Enterprise AI, in production.
    Four desks, one beat.

    PharmaNews

    RTI International Invests in Navidence to Standardize AI-Driven Real-World Evidence

    RTI International invested in Navidence to standardize disease and treatment definitions in AI-driven real-world evidence research across healthcare and life sciences.

    Last updated

    RTI International Invests in Navidence to Standardize AI-Driven Real-World Evidence

    RTI International announced a strategic equity investment in Navidence as the organizations expand efforts to standardize how diseases, treatments, and outcomes are defined in real-world evidence (RWE) research.

    The partnership combines RTI’s scientific research and healthcare evidence expertise with Navidence’s AI-native data and medical informatics platform, according to the announcement published by RTI on May 5.

    RTI said the collaboration will focus on improving consistency and reproducibility across clinical research and healthcare studies, where inconsistent operational definitions often create challenges in comparing datasets, validating findings, and generating regulatory-grade evidence.

    Navidence, founded in 2022, develops Computable Operational Definitions (CODefs), which are standardized human- and machine-readable definitions used to structure diseases, treatments, outcomes, inclusion criteria, and exclusion criteria across studies.

    by AIM Media HouseFree · No paywall

    Keep reading. It's free.

    Create a free Deployed account to finish this story and every story on the site. Choose the briefings you want with it:

    or

    No credit card. One click to unsubscribe. Already a reader? Sign in

    About the author

    Deployed

    Related stories